2012 VIROLOGICAL RESPONSE, SAFETY, AND PHARMACOKINETIC PROFILE FOLLOWING SINGLE- AND MULTIPLE-DOSE ADMINISTRATION OF ACH-0141625 PROTEASE INHIBITOR TO HEALTHY VOLUNTEERS AND HCV GENOTYPE-1 PATIENTS

2011 IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-a AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION A. Neumann, S. Bibert, B. Haagmans, A. Soulier, F. Negro, M. Lagging, C. Ferrari, S. Zeuzem, J.-M. Pawlotsky, S. Schalm, P.-Y. Bochud, DITTO-HCV group. Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Erasmus Medical Center, Rotterdam, The Netherlands; Hopital Henri Mondor – Universite Paris XII, Creteil, France; Hospital University of Geneve, Geneve, Switzerland; University of Goeteborg, Goeteborg, Sweden; Azienda Ospedaliera di Parma, Parma, Italy; University of Frankfurt, Frankfurt, Germany E-mail: neumann@mail.biu.ac.il